Goldline Pharmaceutical Limited (BOM:544759)

India · Delayed Price · Currency is INR

39.25

-1.95 (-4.73%)

At close: Aug 4, 2026

-34.31% (1Y)

Market Cap	376.80M
Revenue (ttm)	311.99M +29.9%
Net Income	41.17M +1,141.3%
EPS	5.97 +979.0%
Shares Out	9.60M
PE Ratio	6.57
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	54,000
Open	40.00
Previous Close	41.20
Day's Range	39.25 - 40.00
52-Week Range	33.00 - 60.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 8, 2026

About Goldline Pharmaceutical

Goldline Pharmaceutical Limited engages in marketing of pharmaceutical products under the Goldline brand in India. It offers goldline pharma, goldline cardinal, goldline aayushman, goldline inLife, and goldline wellness. The company serves physicians, orthopedics, ENT, chest physicians, general and specialty surgery, gastroenterology, neurology, urology, endocrinologists, cardiologists, general physicians, pediatricians, child specialists, neonatologists, intensivists, critical care consultants, and super specialty surgeons. It sells its produc... [Read more]

Industry Drugs, Drug Proprietaries, and Druggists' Sundries

Founded 2004

Country India

Stock Exchange Bombay Stock Exchange

Ticker Symbol 544759

Full Company Profile

Financial Performance

In fiscal year 2026, Goldline Pharmaceutical's revenue was 311.99 million, an increase of 11.20% compared to the previous year's 280.56 million. Earnings were 41.17 million, an increase of 45.26%.

Financial Statements